Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Cisco who wrote (856)	1/5/1998 6:28:00 PM
From: Dana Winrow	Read Replies (1) \| Respond to of 1894

Cisco has asked about NeoPath's Pathfinder: You are correct in your assessment - Neopath is comparing apples and oranges. This might make sense if you are looking at fruit salad, but not when you are considering the cytopathology laboratory. The Pathfinder is not an image-based system; it does not perform any cell analysis. It is a manual system that uses the customer's existing microscope. The features of this device (as cited in the NeoPath press release) make the Pathfinder effective as an inexpensive training tool; the product was not designed to be used in a laboratory-productivity environment. The AcCell is an automated system that can be used alone or in conjunction with a TracCell. The AcCell can be used on the customer's existing microscope. The TracCell, which automatically drives the AcCell, utilizes sophisticated imaging software and has high-precision repeatibility in mapping a slide and presenting material that should be reviewed by a cytotechnologist. In short, the Pathfinder is far from being as comprehensive a system as the AcCell/TracCell system. Dana Winrow Director, Investor Relations AccuMed International, Inc.